BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22396430)

  • 1. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis.
    Rottier WC; Ammerlaan HS; Bonten MJ
    J Antimicrob Chemother; 2012 Jun; 67(6):1311-20. PubMed ID: 22396430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Zahar JR; Lesprit P; Ruckly S; Eden A; Hikombo H; Bernard L; Harbarth S; Timsit JF; Brun-Buisson C;
    Int J Antimicrob Agents; 2017 Jan; 49(1):67-73. PubMed ID: 27890442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
    Schwaber MJ; Carmeli Y
    J Antimicrob Chemother; 2007 Nov; 60(5):913-20. PubMed ID: 17848376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.
    Trecarichi EM; Cauda R; Tumbarello M
    Future Microbiol; 2012 Oct; 7(10):1173-89. PubMed ID: 23030423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
    Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
    Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis.
    Alevizakos M; Karanika S; Detsis M; Mylonakis E
    Int J Antimicrob Agents; 2016 Dec; 48(6):647-654. PubMed ID: 27746102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
    Vardakas KZ; Tansarli GS; Rafailidis PI; Falagas ME
    J Antimicrob Chemother; 2012 Dec; 67(12):2793-803. PubMed ID: 22915465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis.
    Alevizakos M; Gaitanidis A; Andreatos N; Arunachalam K; Flokas ME; Mylonakis E
    Int J Antimicrob Agents; 2017 Nov; 50(5):657-663. PubMed ID: 28705665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases.
    Qureshi ZA; Paterson DL; Peleg AY; Adams-Haduch JM; Shutt KA; Pakstis DL; Sordillo E; Polsky B; Sandkovsky G; Bhussar MK; Doi Y
    Clin Microbiol Infect; 2012 Sep; 18(9):887-93. PubMed ID: 21951551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer].
    García-Gómez M; Guío L; Hernández JL; Vilar B; Pijoán JI; Montejo JM
    Rev Esp Quimioter; 2015 Oct; 28(5):256-62. PubMed ID: 26437756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
    Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
    Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural Ghana, 2007-2012.
    Eibach D; Belmar Campos C; Krumkamp R; Al-Emran HM; Dekker D; Boahen KG; Kreuels B; Adu-Sarkodie Y; Aepfelbacher M; Park SE; Panzner U; Marks F; May J
    Int J Med Microbiol; 2016 Jun; 306(4):249-54. PubMed ID: 27222489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis.
    Shamsrizi P; Gladstone BP; Carrara E; Luise D; Cona A; Bovo C; Tacconelli E
    BMJ Open; 2020 Jan; 10(1):e030266. PubMed ID: 31964661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
    Marchaim D; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Sprecher H; Lachish T; Wiener-Well Y; Alon D; Chowers M; Ciobotaro P; Bardenstein R; Paz A; Potasman I; Giladi M; Schechner V; Schwaber MJ; Klarfeld-Lidji S; Carmeli Y
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5099-104. PubMed ID: 20837757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies.
    Vehreschild MJ; Hamprecht A; Peterson L; Schubert S; Häntschel M; Peter S; Schafhausen P; Rohde H; Lilienfeld-Toal MV; Bekeredjian-Ding I; Libam J; Hellmich M; Vehreschild JJ; Cornely OA; Seifert H
    J Antimicrob Chemother; 2014 Dec; 69(12):3387-92. PubMed ID: 25103492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
    Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
    Son SK; Lee NR; Ko JH; Choi JK; Moon SY; Joo EJ; Peck KR; Park DA
    J Antimicrob Chemother; 2018 Oct; 73(10):2631-2642. PubMed ID: 29800480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.